{"title":"艾伯维(AbbVie)押注210亿美元，认为pharmacyics公司的Imbruvica®将实现上升潜力","authors":"Heather Cartwright","doi":"10.3833/PDR.V2015I3.2099","DOIUrl":null,"url":null,"abstract":"Paying a huge premium to acquire an on-market asset with multi billion dollar revenue potential, AbbVie has trumped Johnson & Johnson (J&J) with a US$21 B deal to acquire Pharmacyclics. Key to the acquisition is Imbruvica® (ibrutinib), a Bruton’s tyrosine kinase (Btk) inhibitor that is approved for a number of B-cell malignancies.The purchase price has shocked many industry observers, effectively valuing Imbruvica as it does at a staggering US$42 B given J&J’s 50% interest in the drug. After being forced to halt its bid to acquire Shire, the deal is another attempt by AbbVie to diversify its business beyond Humira® (adalimumab).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2015I3.2099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Paying a huge premium to acquire an on-market asset with multi billion dollar revenue potential, AbbVie has trumped Johnson & Johnson (J&J) with a US$21 B deal to acquire Pharmacyclics. Key to the acquisition is Imbruvica® (ibrutinib), a Bruton’s tyrosine kinase (Btk) inhibitor that is approved for a number of B-cell malignancies.The purchase price has shocked many industry observers, effectively valuing Imbruvica as it does at a staggering US$42 B given J&J’s 50% interest in the drug. After being forced to halt its bid to acquire Shire, the deal is another attempt by AbbVie to diversify its business beyond Humira® (adalimumab).\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"62 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2015I3.2099\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2015I3.2099","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential
Paying a huge premium to acquire an on-market asset with multi billion dollar revenue potential, AbbVie has trumped Johnson & Johnson (J&J) with a US$21 B deal to acquire Pharmacyclics. Key to the acquisition is Imbruvica® (ibrutinib), a Bruton’s tyrosine kinase (Btk) inhibitor that is approved for a number of B-cell malignancies.The purchase price has shocked many industry observers, effectively valuing Imbruvica as it does at a staggering US$42 B given J&J’s 50% interest in the drug. After being forced to halt its bid to acquire Shire, the deal is another attempt by AbbVie to diversify its business beyond Humira® (adalimumab).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
